Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Urea Cycle Disorders Treatment Market Size Forecast: How Large Could The Market Become By 2030?
The market for treatments addressing urea cycle disorders has experienced consistent expansion in recent years. Valued at $1.37 billion in 2025, it is projected to reach $1.43 billion by 2026, reflecting a compound annual growth rate (CAGR) of 3.8%. This past growth was primarily driven by several factors, including insufficient public knowledge about UCD, a scarcity of therapeutic alternatives, low rates of patient identification, substantial expenses associated with care, and a heavy reliance on hospital-based treatment settings.
The market for treatments addressing urea cycle disorders is projected to experience consistent expansion over the coming years. By 2030, its value is anticipated to reach $1.71 billion, reflecting a compound annual growth rate (CAGR) of 4.6%. This forecasted growth is driven by factors such as progress in gene therapy research, a growing emphasis on precision medicine, improvements in ammonia monitoring technology, a heightened focus on pediatric patients, and the broadening of home healthcare services. Key developments shaping this period include the creation of personalized therapies for UCD, enhanced formulations of ammonia scavengers, advances in enzyme replacement treatments, innovations tailored to children, and the introduction of home-based and remote monitoring systems.
Download A Free Sample Report For Comprehensive Market Insights:
Urea Cycle Disorders Treatment Market Growth Momentum: Which Factors Are Influencing Demand?
A growing prevalence of chronic kidney disease is anticipated to drive expansion in the urea cycle disorders treatment market in the coming period. Chronic kidney disease (CKD) refers to a persistent condition marked by a gradual decline in kidney function over an extended period. This disorder relies on urea cycle disorder treatments to help regulate metabolic waste, especially excessive urea accumulation, since compromised kidney function prevents effective waste removal. As an illustration, data from November 2023 published by Kidney Care UK, a charitable organization providing support to kidney patients in the UK, indicates that around 7.2 million people are thought to have CKD stages 1 through 5, including approximately 3.5 million individuals in the UK who are in the more advanced stages (3-5), where symptoms tend to become increasingly difficult to manage. Consequently, the increasing number of chronic kidney disease cases is fueling progress within the urea cycle disorders treatment market.
Urea Cycle Disorders Treatment Market Segment Analysis Highlighting Growth Areas
The urea cycle disorders treatment market covered in this report is segmented –
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Amino Acid Supplements: Arginine Supplements, Citrulline Supplements, Other Essential Amino Acids
2) By Sodium Phenylbutyrate: Powder Form, Tablet Form
3) By Glycerol Phenylbutyrate: Oral Solutions, Other Forms
4) By Sodium Benzoate: Intravenous Solutions, Oral Formulations
5) By Other Treatments: Liver Transplantation, Dietary Modifications, Enzyme Replacement Therapy, Other Supportive Therapies
Urea Cycle Disorders Treatment Market Trends Reshaping Industry Growth
Leading firms in the urea cycle disorder treatment market are increasingly relying on strategic alliances to advance novel therapies and enhance disease control. Through such partnerships, companies pool their respective capabilities and assets to achieve shared objectives and gains. As a case in point, in June 2024, Orsini Specialty Pharmacy, a personalized care and medication firm based in the United States, teamed up with Zevra Therapeutics Inc., an American company focused on rare disease treatments. They announced Orsini’s appointment as the pharmacy partner for OLPRUVA (sodium phenylbutyrate) oral suspension. OLPRUVA is a prescription drug intended for long-term management of urea cycle disorders (UCDs), used alongside other treatments like dietary adjustments. It targets both adult and pediatric patients who have deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
Urea Cycle Disorders Treatment Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the urea cycle disorders treatment market are Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding, Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics Inc., Orpharma Pty Ltd., Horizon Therapeutics Plc, Synlogic, Amicus Therapeutics, Sobi, PTC Therapeutics, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Protalix BioTherapeutics, Erytech Pharma, Relief Therapeutics Holding AG, Selecta Biosciences Inc., Argenx SE, Dynacure SA, Inventiva SA
Access The Complete Urea Cycle Disorders Treatment Market Report:
Urea Cycle Disorders Treatment Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the urea cycle disorders treatment market in 2025. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model